Evaluation of anti-diabetic activity of Syzygium cumini extract and its phytosome formulation against streptozotocin-induced diabetic rats
Amudha S, Prabal Kumar Manna and Jeganathan NS
The Inner kernel of Syzygium cumini seeds were extracted and formulated in to a novel phytosome formulation by using cholesterol and lecithin with suitable method. The prepared Syzygium cumini seed extract and Syzygium cumini phytosome were studied for the acute oral toxicity, Oral glucose tolerance test (OGTT) and anti-diabetic activity against Streptozotocin-induced rats model. The OGTT and antidiabetic activity was compared with control group (1% w/v gum acacia); the standard drug Glibenclamide (50 mg/kg/po), Syzygium cumini seed extract (100 / 200 and 400mg/kg/po) and its Syzygium cumin phytosome formulation (100 / 200 and 400mg/kg/po). Acute toxicity studies show no mortality and morbidity up to the dose 2000mg/kg of body weight. In OGTT, and antidiabetic activity studies Syzygium cumini seed extract and Syzygium cumin phytosome formulation shows a significant control in blood sugar level in comparison with standard drug Glibenclamide in a dose dependent manner. Further the research proves that phytosome formulation is superior in controlling blood sugar than Syzygium cumini seed extract.
How to cite this article:
Amudha S, Prabal Kumar Manna, Jeganathan NS. Evaluation of anti-diabetic activity of Syzygium cumini extract and its phytosome formulation against streptozotocin-induced diabetic rats. Pharma Innovation 2018;7(6):603-608.